Finanzen von Pharvaris NV (PHVS)PHVSPharvaris NV

Evaluating the bottom line, Pharvaris N.V. maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -70.46%, provide a clear picture of how effectively PHVS converts its operational activities into shareholder value.

In the context of the broader market, PHVS competes directly with industry leaders such as RXRX and PGEN. With a market capitalization of $2.09B, it holds a significant position in the sector. When comparing efficiency, PHVS's gross margin of N/A stands against RXRX's -49.82% and PGEN's 94.90%. Such benchmarking helps identify whether Pharvaris N.V. is trading at a premium or discount relative to its financial performance.

Pharvaris reported a net loss of €47.8 million in Q2 2026, but cash and cash equivalents were €318 million, indicating a solid financial position despite ongoing losses. The company has a current ratio of 11.94, suggesting strong liquidity.